Brain

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast…

3 months ago

Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024

New products complement an already extensive range of products enabling fundamental advancements in neuroscience researchHOLLISTON, Mass., Oct. 03, 2024 (GLOBE…

3 months ago

Positive Data from the First Part of IRLAB’s Phase I Study with the Drug Candidate IRL757

GOTHENBURG, SE / ACCESSWIRE / October 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 3 2024 - IRLAB Therapeutics…

3 months ago

Gut Microbiome Health Tech Innovator, Ixcela Launches Virtual Clinic to Ease Cancer Symptoms After Landmark Roper St. Francis Healthcare Pilot

Gut Microbiome Health Plays Critical Role Reducing Cancer Care Side Effects including Fatigue, Brain Fog, Nausea, Constipation, Sleep and Overall…

3 months ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement…

3 months ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”BOSTON, Oct. 02,…

3 months ago

Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board

INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognos Therapeutics, a private hi-tech medical technology company focused on the development…

3 months ago

Court Ruling: Fluoride Levels Pose Unreasonable Risk to Children’s IQ

“The Court finds that fluoridation of water at 0.7 milligrams per liter (“mg/L”) – the level presently considered “optimal” in…

3 months ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of…

3 months ago

Nexstim Receives NBS System 5 Order from European Customer

Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim…

3 months ago